Therapeutic strategies for rheumatoid arthritis
- PMID: 12776222
- DOI: 10.1038/nrd1109
Therapeutic strategies for rheumatoid arthritis
Abstract
Recent years have seen considerable advances in our understanding of both the clinical and basic-research aspects of rheumatoid arthritis. Clinical progress has come from a better recognition of the natural history of the disease, the development and validation of outcome measures for clinical trials and, consequently, innovative trial designs. In parallel, basic research has provided clues to the pathogenic events underlying rheumatoid arthritis, and advances in biotechnology have facilitated the development of new classes of therapeutics. Here, we summarize the fruits of these advances: innovative approaches to the use of existing, traditional disease-modifying antirheumatic drugs; novel agents approved very recently; and further avenues that are presently under investigation or which are of more distant promise.
Similar articles
-
Are biologics more effective than classical disease-modifying antirheumatic drugs?Arthritis Res Ther. 2008;10(5):118. doi: 10.1186/ar2491. Epub 2008 Sep 19. Arthritis Res Ther. 2008. PMID: 18828888 Free PMC article.
-
Early rheumatoid arthritis.Curr Opin Rheumatol. 2006 May;18(3):282-8. doi: 10.1097/01.bor.0000218950.27483.80. Curr Opin Rheumatol. 2006. PMID: 16582693 Review.
-
Biologic therapy for early rheumatoid arthritis: the latest evidence.Curr Opin Rheumatol. 2008 May;20(3):314-9. doi: 10.1097/BOR.0b013e3282f5fcf6. Curr Opin Rheumatol. 2008. PMID: 18388524 Review.
-
Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?Arthritis Rheum. 2003 Jun;48(6):1481-3. doi: 10.1002/art.11141. Arthritis Rheum. 2003. PMID: 12794813 No abstract available.
-
Innovative treatment strategies for patients with rheumatoid arthritis.Curr Opin Rheumatol. 2008 May;20(3):287-94. doi: 10.1097/BOR.0b013e3282fa13db. Curr Opin Rheumatol. 2008. PMID: 18388520 Review.
Cited by
-
Treatment with anti-NAP monoclonal antibody reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis.Clin Exp Immunol. 2013 Feb;171(2):155-63. doi: 10.1111/cei.12009. Clin Exp Immunol. 2013. PMID: 23286942 Free PMC article.
-
Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver.J Immunol Res. 2016;2016:7509653. doi: 10.1155/2016/7509653. Epub 2016 Jul 31. J Immunol Res. 2016. PMID: 27556049 Free PMC article.
-
ROS-Responsive Berberine Polymeric Micelles Effectively Suppressed the Inflammation of Rheumatoid Arthritis by Targeting Mitochondria.Nanomicro Lett. 2020 Mar 20;12(1):76. doi: 10.1007/s40820-020-0410-x. Nanomicro Lett. 2020. PMID: 34138288 Free PMC article.
-
The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis.Naunyn Schmiedebergs Arch Pharmacol. 2006 May;373(2):140-7. doi: 10.1007/s00210-006-0062-5. Epub 2006 Apr 26. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16703402
-
[Drug therapy of rheumatoid arthritis].Orthopade. 2003 Dec;32(12):1095-103. doi: 10.1007/s00132-003-0560-9. Orthopade. 2003. PMID: 14655006 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical